SAPPHIRe III in Taiwan－Progression Evaluation and Cardiovascular Outcomes of Hypertensive Families

Hypertension Clinical Trial

Official title:

Progression Evaluation and Cardiovascular Outcomes of Hypertensive Families－A Follow-up Genetic Study of Taiwan SAPPHIRe Cohort

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00631956
• Other study ID #: EC0950806
• Status: Active, not recruiting
• Phase: N/A
• First received: March 3, 2008
• Last updated: April 5, 2016
• Start date: October 2006
• Est. completion date: December 2016

Study information

• Verified date: March 2016
• Source: National Health Research Institutes, Taiwan
• Contact: n/a
• Is FDA regulated: No
• Health authority: Taiwan: Department of Health
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to determine the progression evaluation, cardiovascular outcomes, and genetic determinations of hypertension in Chinese

Description:

Blood pressure is a quantitative trait affected by both genetic and environmental factors. Stanford-Asian Pacific Program in Hypertension and Insulin Resistance (SAPPHIRe) is an international genetic study, which intends to map the major genetic loci underlying hypertension in sibpairs of Asian-Pacific Chinese and Japanese origin.

Success in genetic studies may depend on many factors including the selection of the patient population, the identification of intermediate phenotypes, the disease subsets, and the genetic strategy and methodologies employed.

In order to reduce heterogeneity of the genetic and environmental background, we will focus our investigation on the Chinese population. Furthermore, besides the variables associated with insulin resistance, which were collected and studied in year 1 through 5 of SAPPHIRe, some more variables from echocardiographic examination and multi-detector row computed tomography (MDCT) will be collected and studied.

Hypertension is a major risk factor for stroke, myocardial infraction and renal disease. Hypertension often occurs in combination with other metabolic complications such as hyperlipidemia, obesity and insulin resistance. The combined disorder is often called the metabolic syndrome.

Our general approach is to continue analyzing candidate genes as well as perform a complete genome search based on the exiting genome-wide scan data together with old and new phenotype variables. Our objective is to identify susceptible gene for hypertension through incorporating intermediate phenotypes and to find gene markers for developing useful screening tools for the high risk group in order to prevent or early detect cardiovascular disorder patients.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 1038
• Est. completion date: December 2016
• Est. primary completion date: December 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 40 Years to 70 Years

Eligibility

Inclusion Criteria:

• Age of subjects when recruited must be between 35 and 60 years. Subjects over age 60 may also be eligible provided that documentation of their hypertension status prior to age 60 is available.

• Chinese ancestry, i.e. all four grandparents Chinese. Hypertension is defined as follows: systolic BP (SBP) greater than or equal to (>=) 160 mm Hg or diastolic BP (DBP) >= 95 mm Hg or taking 2 medications for high blood pressure (Stage II hypertension). Alternatively the subject could have uncontrolled hypertension, i.e. taking 1 medication for high blood pressure and has either systolic BP >= 140 or diastolic >= 90 mm Hg.

Exclusion Criteria:

• One of the affected sibs is adopted (i.e. no parent in common) or if the sibs have only one parent in common.

• Both parents have been treated for hypertension before the age of 60. If offspring reports about their parents' hypertension status are conflicting, then a single reliable report of hypertension in both parents before age 60 is cause for exclusion. This exclusion criterion, however, does not apply to discordant sib-pairs.

• Diabetic individuals were excluded. Diabetes uncovered as a result of SAPPHIRe lab work does not lead to exclusion however.

• Severe kidney disease (except stones and remote infections) of creatinine > 1.5 mg/dl, unless documented proof that the subject met inclusion criteria prior to increase in creatinine levels.

• A body-mass index greater than 35.

• In addition, the following conditions are considered as cause for exclusion: ongoing (or within the past 6 months) treatment for cancer; terminal illness (life expectancy fewer than 6 months); liver cirrhosis or any other chronic illness; pregnancy or fewer than 6 months post-partum.

Study Design

Observational Model: Family-Based, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Hypertension

Locations

Country	Name	City	State
Taiwan	Division of Biostatistics and Bioinformatics, NHRI	Miaoli county

Sponsors (5)

Lead Sponsor	Collaborator
National Health Research Institutes, Taiwan	National Taiwan University Hospital, Taichung Veterans General Hospital, Taipei Veterans General Hospital, Taiwan, Tri-Service General Hospital

Country where clinical trial is conducted

Taiwan,